Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
>
Disorders
>
Disease or Syndrome
>
Oral Mucositis
Oral Mucositis
Oral mucositis is a common and debilitating side effect of cancer treatments, characterized by inflammation and ulceration of the oral cavity.
This condition can have a significant impact on a patient's quality of life, making it difficult to eat, drink, and speak.
PubCompare.ai's AI-powered platform can streamline oral mucositis research by helping researchers locate the best protocols from literature, pre-prints, and patents, and identify the optimal products through intelligent analysis.
This powerful tool enhances oral mucositis research protocols by enabling comparisons and optimiztion, ensuring researchers can focus on developing effective treatments to improve patient outcomes.
This condition can have a significant impact on a patient's quality of life, making it difficult to eat, drink, and speak.
PubCompare.ai's AI-powered platform can streamline oral mucositis research by helping researchers locate the best protocols from literature, pre-prints, and patents, and identify the optimal products through intelligent analysis.
This powerful tool enhances oral mucositis research protocols by enabling comparisons and optimiztion, ensuring researchers can focus on developing effective treatments to improve patient outcomes.
Most cited protocols related to «Oral Mucositis»
Adult
Brain Stem
Combined Modality Therapy
Deglutition Disorders
Esophagitis
Fatigue
Hearing Impairment
Hypothyroidism
Injuries
Laryngeal Edema
Linear Accelerators
Neoplasm Metastasis
Neural-Optical Lesion
Oral Mucositis
Patients
Physicians
Radiation
Xerostomia
Was defined by: a) Global NIH scoring: patients had mild cGVHD if only 1 or 2 organs (except lungs) were involved, with a maximum score 1 in all affected organs. Moderate cGVHD involved at least 1 organ with clinically significant, but not major disability (maximum score 2); or 3 or more organs with no clinically significant functional impairment (maximum score 1 in all affect organs). A lung score 1 was classified as moderate. Severe cGVHD indicated major impairment caused by cGVHD (score 3 in any organ). Lung scores of 2 or 3 were classified as severe. Organs scored included the skin, eyes, mouth, GI tract, liver, lungs, and joint/fascia. The genital area was scored in females only20 (link); b) NIH average score which is a result of total NIH score for each of the organ systems divided by the total number of organ systems analyzed (8 for female and 7 for male); c) Lee symptom scale: degree of patient bother with cGVHD symptoms. It is a 30-item symptom scale with 7 subscales which correlate highly with patients' self-assessed mild, moderate, and severe cGVHD manifestations23 (link); d) using the physical component summary (PCS) scale, drawn from the SF-36 v.2, a well validated measure of self-assessed health24 (link); e) Schirmer's tear test performed in each eye with anesthesia scored from 0-30 mm; f) Oral Mucositis Rating Scale (OMRS) a rating scale (0-273) used to grade and measure oral changes including erythema, atrophy and ulceration25 (link); g) Percentage of skin body surface area (BSA) affected by: erythema, moveable sclerotic skin manifestations, and non-moveable skin changes and fasciitis.22 (link)
Anesthesia
Atrophy
Body Surface Area
Disabled Persons
Erythema
Fascia
Fasciitis
Females
Gastrointestinal Tract
Genitalia
Joints
Liver
Lung
Males
Oral Cavity
Oral Mucositis
Patients
Physical Examination
Sclerosis
Skin
Skin Manifestations
Tears
Woman
Acepromazine
Agar
Animals
Autopsy
Biological Assay
Blood
Candida
Candida albicans
Cheek
Dissection
Edetic Acid
Epithelium
Euthanasia
Freezing
Gossypium
Infection
isolation
Ketamine
Mus
Normal Saline
Oral Cavity
Oral Mucositis
Proteins
RNA, Messenger
Serum
Sinuses, Nasal
Sterility, Reproductive
Technique, Dilution
Tetracycline
Tissues
Tongue
FMT was performed through oral gavage of mucus (first day) and faeces (second and third days) preparations from donor mice. This protocol facilitates the engraftment of the mucus-associated bacteria. Donor mice were untreated (normobiotic) donors, DSS-treated (dysbiotic) or treated with metronidazole (1 g/L), vancomycin (1 g/L), streptomycin (2 g/L) or a cocktail of the three antibiotics combined in order to deplete distinct taxa of bacteria. Mucus was scraped from colons, diluted in PBS and administered to recipients at 1:1 ratio. Faeces were collected, diluted in PBS (50 mg/ml) and administered to recipients by oral gavage (10 mg/mouse) one day after the end of acute DSS administration.
For in vivo IL-10R blockade, mice were injected intraperitoneally with 250 µg InVivoMAb anti-mouse IL-10R (BioXCell, clone 1B1.3 A), or its Isotype (BioXCell), daily for 4 days starting from one day before FMT treatment.
For in vivo IL-10R blockade, mice were injected intraperitoneally with 250 µg InVivoMAb anti-mouse IL-10R (BioXCell, clone 1B1.3 A), or its Isotype (BioXCell), daily for 4 days starting from one day before FMT treatment.
Full text: Click here
Antibiotics, Antitubercular
Bacteria
Clone Cells
Colon
Donors
Dysbiosis
Feces
Immunoglobulin Isotypes
Metronidazole
Mucus
Mus
Oral Mucositis
Receptor, Interleukin-10
Streptomycin
Tube Feeding
Vancomycin
We analyzed data from the patient population enrolled in the SELECT BC study that completed both the EQ-5D-3L and EORTC QLQ-C30 questionnaires at baseline. Because AEs were not assessed after the study treatment, we included only the EQ-5D-3L and EORTC QLQ-C30 measured before the end of the last course of the study treatment. We summarized profiles of health utility and HRQOL, and calculated completion rates, defined as the number of completed questionnaires divided by the number of expected responses, excluding patients after the study treatment. We examined predictive factors of incomplete assessments using a multivariable logistic generalized estimating equation.
For processing AE data, we chose 15 non-hematological AEs relevant to the treatment of metastatic breast cancer: febrile neutropenia, fever, fatigue, alopecia, allergy, diarrhea, oral mucositis, nausea, vomiting, anorexia, edema, motor neuropathy, sensory neuropathy, arthralgia, and myalgia. We then identified the last grade of each AE immediately before EQ-5D-3L and EORTC QLQ-C30 assessment (i.e. 3, 6, and 12 months). We counted the total number of incidences for each AE at three time points, and calculated the difference between incidence date of AEs and assessment date of the EQ-5D-3L and EORTC QLQ-C30. Finally, we selected AEs with ten or more incidences for subsequent analysis, meaning that we did not analyze AEs with fewer incidences because those estimates that essentially reflect the small number of assessments would be unstable and imprecise.
We used linear marginal mean models with time-dependent AEs to quantify the impact of each AE on health utility and HRQOL [27 ]. Analyses using the linear marginal mean model were adjusted for baseline scores, age, treatment, time, and treatment-by-time interaction (see Online Resource 1 for more details) [28 ]. First, we conducted separate analysis, where only a single analyzable AE (i.e. ten or more incidences) was included in the model. We then conducted simultaneous analysis, where all analyzable AEs were included in the models. Grades of AEs were modeled using linear and quadratic terms. We fitted the models using the generalized estimating equation method [27 ].
All analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). All p value evaluations were two-sided, and a p value < 0.05 was considered nominally statistically significant without multiplicity adjustment.
For processing AE data, we chose 15 non-hematological AEs relevant to the treatment of metastatic breast cancer: febrile neutropenia, fever, fatigue, alopecia, allergy, diarrhea, oral mucositis, nausea, vomiting, anorexia, edema, motor neuropathy, sensory neuropathy, arthralgia, and myalgia. We then identified the last grade of each AE immediately before EQ-5D-3L and EORTC QLQ-C30 assessment (i.e. 3, 6, and 12 months). We counted the total number of incidences for each AE at three time points, and calculated the difference between incidence date of AEs and assessment date of the EQ-5D-3L and EORTC QLQ-C30. Finally, we selected AEs with ten or more incidences for subsequent analysis, meaning that we did not analyze AEs with fewer incidences because those estimates that essentially reflect the small number of assessments would be unstable and imprecise.
We used linear marginal mean models with time-dependent AEs to quantify the impact of each AE on health utility and HRQOL [27 ]. Analyses using the linear marginal mean model were adjusted for baseline scores, age, treatment, time, and treatment-by-time interaction (see Online Resource 1 for more details) [28 ]. First, we conducted separate analysis, where only a single analyzable AE (i.e. ten or more incidences) was included in the model. We then conducted simultaneous analysis, where all analyzable AEs were included in the models. Grades of AEs were modeled using linear and quadratic terms. We fitted the models using the generalized estimating equation method [27 ].
All analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). All p value evaluations were two-sided, and a p value < 0.05 was considered nominally statistically significant without multiplicity adjustment.
Alopecia
Anorexia
Arthralgia
Diarrhea
Edema
Fatigue
Febrile Neutropenia
Fever
Hypersensitivity
Malignant Neoplasm of Breast
Myalgia
Nausea
Neuritis, Motor
Oral Mucositis
Patients
Most recents protocols related to «Oral Mucositis»
The presence and severity of oral mucositis and candidiasis were assessed in all participants at three-time points of the study: i) on the day of the first RT session (initial assessment); ii) halfway through RT treatment (intermediate assessment); and iii) on the day of the last RT session (final assessment). The intermediate evaluation occurred between the 14th and 20th RT sessions for the participants assigned to the GConv and between the 8th and 12th sessions for the GHipo.
Oral mucositis was evaluated according to the methodology proposed by the World Health Organization (WHO), which established the classification criteria to assess this oral mucosa condition [20 ]. It is a visual and noninvasive evaluation of the oral cavity, where the categorization follows the following parameters: grade 0, no changes; grade 1, pain/erythema; grade 2, erythema and ulcers; grade 3, ulcers (liquid diet only); grade 4, it is not possible to ingest food.
The presence of pseudomembranous candidiasis was clinically evaluated [21 (link)]. This evaluation was based on the observation of anatomic localization, features, and removal of the pseudomembrane by rubbing the lesion with gauze, with the adjacent mucosa appearing normal or erythematous, usually painless [21 (link)].
Both evaluations were performed on all participants by a single operator with extensive academic training in dentistry and clinical experience, properly trained in all stages proposed to minimize biases related to different perceptions of the oral condition of the participants. In addition to visual evaluation, the participant was also asked about the intensity of pain and difficulty swallowing food.
Oral mucositis was evaluated according to the methodology proposed by the World Health Organization (WHO), which established the classification criteria to assess this oral mucosa condition [20 ]. It is a visual and noninvasive evaluation of the oral cavity, where the categorization follows the following parameters: grade 0, no changes; grade 1, pain/erythema; grade 2, erythema and ulcers; grade 3, ulcers (liquid diet only); grade 4, it is not possible to ingest food.
The presence of pseudomembranous candidiasis was clinically evaluated [21 (link)]. This evaluation was based on the observation of anatomic localization, features, and removal of the pseudomembrane by rubbing the lesion with gauze, with the adjacent mucosa appearing normal or erythematous, usually painless [21 (link)].
Both evaluations were performed on all participants by a single operator with extensive academic training in dentistry and clinical experience, properly trained in all stages proposed to minimize biases related to different perceptions of the oral condition of the participants. In addition to visual evaluation, the participant was also asked about the intensity of pain and difficulty swallowing food.
Full text: Click here
Candidiasis
Dental Caries
Diet
Erythema
Food
Mouth Diseases
Mucous Membrane
Oral Examination
Oral Mucositis
Pain
Perceptual Disorders
Severity, Pain
Ulcer
In order to extract dishes related to CRDFs and non-CRDFs, 1279 dishes consumed by participants in the 2016–2018 Korean National Health and Nutrition Examination Survey were used. Contribution analysis (CA) and variability analysis (VA) were performed to select FFQ dish items. CA is a statistical method that calculates the cumulative contribution of a dish to each DF. For example, all dishes can contribute to energy, but CA will sort all dishes by their highest contribution first. When selecting dishes that contributed up to 90% of the 21 DFs, 579 dishes met these criteria. Therefore, we selected dishes until the cumulative ratio of each DF reached 50%. VA is a statistical method that calculates the between-individual variance of dish intake for DF through multivariate regression analysis. VA enabled us to select dish items while considering inter-individual variability. When we selected dishes that contributed up to 90% of the 21 DFs, 438 dishes met these criteria, and 88 dishes contributed up to 50%. Therefore, we included dishes up to the point where the cumulative sum of VA was 70%.
Of the 1279 dishes eaten by the participants, the final dish lists were selected using the CA and VA methods. A total of 196 dish items were extracted. After regrouping based on the similarity of main ingredients and cooking method, a final 107 dish items were selected. Then, honey and ginger were added to the FFQ list (Figure 1 ) because they are known to reduce the side effects of anti-cancer treatment. A meta-analysis has reported that honey can enhance the therapeutic efficacy of patients with cancer and delay and reduce the onset of oral mucositis [19 (link),20 (link),21 (link),22 (link)]. Ginger is also a traditional vomiting remedy [23 (link)] and may reduce nausea, vomiting, and fatigue [24 (link)].
Of the 1279 dishes eaten by the participants, the final dish lists were selected using the CA and VA methods. A total of 196 dish items were extracted. After regrouping based on the similarity of main ingredients and cooking method, a final 107 dish items were selected. Then, honey and ginger were added to the FFQ list (
Full text: Click here
Eating
Fatigue
ginger extract
Honey
Hyperostosis, Diffuse Idiopathic Skeletal
Koreans
Malignant Neoplasms
Nausea
Oral Mucositis
Patients
Therapeutics
In each group, chemotherapy and the induction of oral mucositis were carried out as previously described by Katagiri et al. [1 (link)], and inoculation with Candida albicans was performed as described by Takakura et al. [9 (link)]. Briefly, for chemotherapy, 7 mg/kg cisplatin on day 1 and 10 mg/kg 5-fluorouracil on days 1, 2, 3, and 4 were intraperitoneally injected into the mice. For C. albicans inoculation, 5.0 × 106 cells/25 µL of the ATCC 48130 strain were orally administered at day 2, 3, and 5 of chemotherapy. Prophylactic treatment in Groups A, B, and C was performed on days 3, 4, and 5 (Figure 1 ). In Group A, the mouth was carefully cleaned with sterile cotton and saline until no removable stains remained in the entire mouth. In Group B, 2% miconazole gel was administrated orally at 60 mg/kg with sterile cotton (Mochida Pharmaceutical, Tokyo, Japan). In Group C, fluconazole 1 mg/mL (Pfizer, Tokyo, Japan) was administrated intravenously at 0.52 mg/kg. All mice were sacrificed on day 6 with a lethal dose of general anesthesia. At the same time, a blood sample for culture and polymerase chain reaction (PCR) was taken from the cardiac apex without any contamination.
Full text: Click here
Blood Culture
Candida albicans
Cisplatin
Condoms
Cultured Cells
Fluconazole
Fluorouracil
General Anesthesia
Gossypium
Heart
Mice, House
Miconazole
Oral Cavity
Oral Mucositis
Pharmaceutical Preparations
Pharmacotherapy
Polymerase Chain Reaction
Saline Solution
Staining
Sterility, Reproductive
Vaccination
Population-based retrospective cohort data came from Korea National Health Insurance claims for 172,462 primiparous women aged 25–40 and delivered in 2017. This retrospective cohort study was approved by the Institutional Review Board (IRB) of Korea University Anam Hospital on 5 November 2018 (2018AN0365). Informed consent was waived by the IRB.
The dependent variable was PTB (birth before 37 weeks of gestation) in 2017. Four categories of PTB were introduced according to the ICD-10 Code: (1) PTB 1—PTB with premature rupture of membranes (PROM) only; (2) PTB 2—preterm labor and birth without PROM; (3) PTB 3—PTB 1 or PTB 2; (4) PTB 4—PTB 3 or other indicated PTB (Table S1 ). The 188 independent variables covered the following information: (1) demographic/socioeconomic determinants in 2016, including age and socioeconomic status measured by an insurance fee with the range of 1 (the highest socioeconomic group) to 20 (the lowest socioeconomic group); (2) dental diseases for any of the years 2002–2016, i.e., dental cavity, oral mucositis, periodontitis, salivary gland disease, tooth loss; (3) gastrointestinal diseases for any of the years 2002–2016, i.e., Crohn’s disease, gastroesophageal reflux disease (GERD), irritable bowel syndrome, ulcerative colitis; (4) obstetric history in 2016, that is, infertility; (5) medication history in 2016 including benzodiazepine, calcium channel blocker, nitrate, progesterone, sleeping pill, and tricyclic antidepressant. The selection of these 186 independent variables were based on previous studies and data availability. These data on disease and medication history were screened from ICD-10 and ATC codes, respectively (Supplementary Tables S1 and S2 ).
The dependent variable was PTB (birth before 37 weeks of gestation) in 2017. Four categories of PTB were introduced according to the ICD-10 Code: (1) PTB 1—PTB with premature rupture of membranes (PROM) only; (2) PTB 2—preterm labor and birth without PROM; (3) PTB 3—PTB 1 or PTB 2; (4) PTB 4—PTB 3 or other indicated PTB (
Full text: Click here
Benzodiazepines
Calcium Channel Blockers
Childbirth
Crohn Disease
Dental Caries
Dental Diseases
Ethics Committees, Research
Fetal Membranes, Premature Rupture
Gastroesophageal Reflux Disease
Gastrointestinal Diseases
Irritable Bowel Syndrome
National Health Insurance
Nitrates
Oral Mucositis
Periodontitis
Pharmaceutical Preparations
Pregnancy
Premature Obstetric Labor
Progesterone
Salivary Gland Diseases
Sleeping Pills
Sterility, Reproductive
Tooth Loss
Tricyclic Antidepressive Agents
Ulcerative Colitis
Woman
For oral mucositis index scoring, mice were anesthetized with isoflurane every 24–48 h. Mice induction was briefly done in a chamber at 5% isoflurane in oxygen until the loss of the righting reflex occurred. Animals were then left in the chamber with isoflurane 2% in oxygen for 2–3 min before being removed to perform the oral mucositis scoring. The time required for mice examination and image collection for each mouse was approximately 2–3 min.
At the end of each experimental time point (specifically days, 14, 16, and 19 of the experiment), and after weighing the animals, mice were euthanized by exsanguination via cardiac puncture under general anaesthesia. Briefly, general anaesthesia was induced in a chamber at 5% isoflurane in oxygen until loss of the righting reflex occurred. Animals were then maintained on 2–3% isoflurane via a nose cone and laid on the back, and a 25–26 gouge needle was inserted into the heart at a 15–30° angle from the point just beyond the sternum. Negative pressure was applied slowly to withdraw the maximum amount of blood (~ 1 ml) from the heart. To ensure the mice were dead, cervical dislocation was also performed.
The general anaesthesia procedure and post procedure monitoring were conducted in accordance with the Melbourne University’s “General anaesthesia for mice and rats” Animal Care and Use Standard.
At the end of each experimental time point (specifically days, 14, 16, and 19 of the experiment), and after weighing the animals, mice were euthanized by exsanguination via cardiac puncture under general anaesthesia. Briefly, general anaesthesia was induced in a chamber at 5% isoflurane in oxygen until loss of the righting reflex occurred. Animals were then maintained on 2–3% isoflurane via a nose cone and laid on the back, and a 25–26 gouge needle was inserted into the heart at a 15–30° angle from the point just beyond the sternum. Negative pressure was applied slowly to withdraw the maximum amount of blood (~ 1 ml) from the heart. To ensure the mice were dead, cervical dislocation was also performed.
The general anaesthesia procedure and post procedure monitoring were conducted in accordance with the Melbourne University’s “General anaesthesia for mice and rats” Animal Care and Use Standard.
Full text: Click here
Anesthesia, Cardiac Procedures
Animals
BLOOD
Exsanguination
General Anesthesia
Heart
Isoflurane
Joint Dislocations
Mice, Laboratory
Neck
Needles
Nose
Oral Mucositis
Oxygen
Plant Cone
Pressure
Punctures
Rattus norvegicus
Sternum
Top products related to «Oral Mucositis»
Sourced in Japan, Germany, United States
The EOS 60D is a digital single-lens reflex (DSLR) camera manufactured by Canon. It features a 18.0-megapixel CMOS sensor, DIGIC 4 image processor, and a 3.0-inch fully articulated LCD screen. The camera is capable of recording full HD 1080p video at 30 frames per second.
Sourced in United States, Japan, United Kingdom, Austria, Germany, Czechia, Belgium, Denmark, Canada
SPSS version 22.0 is a statistical software package developed by IBM. It is designed to analyze and manipulate data for research and business purposes. The software provides a range of statistical analysis tools and techniques, including regression analysis, hypothesis testing, and data visualization.
Sourced in United States, United Kingdom, Germany, Japan, Belgium, Austria, China, Denmark, Spain
SPSS 22.0 is a statistical software package developed by IBM. It is designed to analyze and manipulate data, providing users with a range of statistical tools and techniques for various applications, including market research, survey data analysis, and social science research.
Sourced in United States, Japan, United Kingdom, Germany, Austria, Belgium, China, Italy, India, Israel, France, Spain, Denmark, Canada, Hong Kong, Poland, Australia
SPSS is a software package used for statistical analysis. It provides a graphical user interface for data manipulation, statistical analysis, and visualization. SPSS offers a wide range of statistical techniques, including regression analysis, factor analysis, and time series analysis.
Sourced in Japan
The EM-140 DG Ring Flash is a compact, high-performance ring flash designed for use in electron microscopy applications. It provides uniform and efficient illumination around the sample, enabling detailed imaging and analysis. The core function of the EM-140 DG Ring Flash is to deliver consistent, adjustable lighting during electron microscope operations.
Sourced in United States
The Philips SL 7520 is a laboratory equipment designed for general use. It is a compact and versatile device that can be utilized in various scientific and research applications.
Sourced in United States, United Kingdom, Japan, Austria
SPSS Statistics for Windows, Version 24.0 is a comprehensive software package for statistical analysis. It provides a wide range of statistical procedures for data management, analysis, and presentation. The software is designed to handle complex data structures and offers a user-friendly interface for conducting statistical analysis.
Sourced in United States, Japan, United Kingdom, Belgium, Austria, Australia, Spain
SPSS is a comprehensive statistical software package that enables data analysis, data management, and data visualization. It provides a wide range of statistical techniques, including descriptive statistics, bivariate analysis, predictive analytics, and advanced modeling. SPSS is designed to help users efficiently manage and analyze large datasets, making it a valuable tool for researchers, statisticians, and data analysts.
Sourced in United States
Karat software is a data acquisition and processing solution designed for mass spectrometry instrumentation. It provides a comprehensive platform for managing and analyzing mass spectrometry data. The software's core function is to enable users to capture, visualize, and process mass spectrometry data efficiently.
Sourced in United States, Austria, Japan, Belgium, New Zealand, Denmark
R version 4.0.2 is the latest stable release of the R Project for Statistical Computing, a free and open-source software environment for statistical computing and graphics. R version 4.0.2 provides a wide range of statistical and graphical techniques, and is widely used in various fields for data analysis, visualization, and modeling.
More about "Oral Mucositis"
Oral mucositis is a common and debilitating side effect of cancer treatments, characterized by inflammation and ulceration of the oral cavity.
This condition, also known as stomatitis or oral inflammation, can have a significant impact on a patient's quality of life, making it difficult to eat, drink, and speak.
The condition is often seen in individuals undergoing chemotherapy, radiation therapy, or hematopoietic stem cell transplantation.
Factors that can increase the risk of developing oral mucositis include the type and dosage of treatment, the use of certain medications, and the presence of pre-existing oral health issues.
Symptoms of oral mucositis may include redness, swelling, pain, and the formation of sores or ulcers in the mouth and throat.
In severe cases, the condition can lead to complications such as infection, dehydration, and malnutrition.
Researchers utilizing tools like PubCompare.ai's AI-powered platform can streamline their investigations into oral mucositis.
This powerful tool can help locate the best protocols from literature, pre-prints, and patents, and identify the optimal products through intelligent analysis.
By enabling comparisons and optimization, PubCompare.ai enhances oral mucositis research protocols, allowing researchers to focus on developing effective treatments to improve patient outcomes.
In addition to PubCompare.ai, researchers may also leverage other advanced tools and software, such as SPSS version 22.0, SPSS Statistics for Windows, Version 24.0, and R version 4.0.2, to analyze data and uncover insights related to oral mucositis.
By harnessing the power of these technologies, researchers can streamline their workflows, optimize their research processes, and ultimately drive progress in the field of oral mucositis management and treatment.
This condition, also known as stomatitis or oral inflammation, can have a significant impact on a patient's quality of life, making it difficult to eat, drink, and speak.
The condition is often seen in individuals undergoing chemotherapy, radiation therapy, or hematopoietic stem cell transplantation.
Factors that can increase the risk of developing oral mucositis include the type and dosage of treatment, the use of certain medications, and the presence of pre-existing oral health issues.
Symptoms of oral mucositis may include redness, swelling, pain, and the formation of sores or ulcers in the mouth and throat.
In severe cases, the condition can lead to complications such as infection, dehydration, and malnutrition.
Researchers utilizing tools like PubCompare.ai's AI-powered platform can streamline their investigations into oral mucositis.
This powerful tool can help locate the best protocols from literature, pre-prints, and patents, and identify the optimal products through intelligent analysis.
By enabling comparisons and optimization, PubCompare.ai enhances oral mucositis research protocols, allowing researchers to focus on developing effective treatments to improve patient outcomes.
In addition to PubCompare.ai, researchers may also leverage other advanced tools and software, such as SPSS version 22.0, SPSS Statistics for Windows, Version 24.0, and R version 4.0.2, to analyze data and uncover insights related to oral mucositis.
By harnessing the power of these technologies, researchers can streamline their workflows, optimize their research processes, and ultimately drive progress in the field of oral mucositis management and treatment.